Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...